DNA Damage Induced by Alkylating Agents and Repair Pathways

The cytotoxic effects of alkylating agents are strongly attenuated by cellular DNA repair processes, necessitating a clear understanding of the repair mechanisms. Simple methylating agents form adducts at N- and O-atoms. N-methylations are removed by base excision repair, AlkB homologues, or nucleotide excision repair (NER). O 6-methylguanine (MeG), which can eventually become cytotoxic and mutagenic, is repaired by O 6-methylguanine-DNA methyltransferase, and O 6MeG:T mispairs are recognized by the mismatch repair system (MMR). MMR cannot repair the O 6MeG/T mispairs, which eventually lead to double-strand breaks. Bifunctional alkylating agents form interstrand cross-links (ICLs) which are more complex and highly cytotoxic. ICLs are repaired by complex of NER factors (e.g., endnuclease xeroderma pigmentosum complementation group F-excision repair cross-complementing rodent repair deficiency complementation group 1), Fanconi anemia repair, and homologous recombination. A detailed understanding of how cells cope with DNA damage caused by alkylating agents is therefore potentially useful in clinical medicine.

[1]  H. Nakase,et al.  DNA ligase IV is a potential molecular target in ACNU sensitivity , 2010, Cancer science.

[2]  B. Kaina,et al.  Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles , 2010, Cell cycle.

[3]  H. Nakase,et al.  DNA ligase IV as a new molecular target for temozolomide. , 2009, Biochemical and biophysical research communications.

[4]  A. Takahashi,et al.  DNA double-strand breaks: their production, recognition, and repair in eukaryotes. , 2009, Mutation research.

[5]  L. Thompson,et al.  Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. , 2009, Mutation research.

[6]  K. Miyagawa,et al.  Clinical importance of DNA repair inhibitors in cancer therapy , 2009 .

[7]  M. Christmann,et al.  Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53 , 2009, British Journal of Cancer.

[8]  Thomas Helleday,et al.  DNA repair pathways as targets for cancer therapy , 2008, Nature Reviews Cancer.

[9]  M. Lopes,et al.  Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. , 2007, Genes & development.

[10]  M. Middleton,et al.  The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors , 2007, Expert opinion on investigational drugs.

[11]  M. Christmann,et al.  MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. , 2007, DNA repair.

[12]  T. Helleday,et al.  DNA double-strand break repair: from mechanistic understanding to cancer treatment. , 2007, DNA repair.

[13]  S. West,et al.  Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. , 2007, Molecular cell.

[14]  J. Cairncross,et al.  O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. , 2007, Cancer research.

[15]  C. Mathew,et al.  A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M , 2005, Nature Genetics.

[16]  Karen H. Almeida,et al.  The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. , 2005, Cancer research.

[17]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[18]  Zhao-Qi Wang,et al.  Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Finn Drabløs,et al.  Alkylation damage in DNA and RNA--repair mechanisms and medical significance. , 2004, DNA repair.

[20]  J. Jiricny,et al.  Mismatch repair and DNA damage signalling. , 2004, DNA repair.

[21]  N. Curtin,et al.  Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells , 2004, Clinical Cancer Research.

[22]  W. Hamel,et al.  Pattern of Recurrence following Local Chemotherapy with Biodegradable Carmustine (BCNU) Implants in Patients with Glioblastoma , 2004, Journal of Neuro-Oncology.

[23]  M. Christmann,et al.  Mechanisms of human DNA repair: an update. , 2003, Toxicology.

[24]  Samuel H. Wilson,et al.  Base Excision Repair Intermediates Induce p53-independent Cytotoxic and Genotoxic Responses* , 2003, Journal of Biological Chemistry.

[25]  Samuel H. Wilson,et al.  Localization of the Deoxyribose Phosphate Lyase Active Site in Human DNA Polymerase ι by Controlled Proteolysis* , 2003, Journal of Biological Chemistry.

[26]  J. Lamerdin,et al.  Fanconi Anemia FANCG Protein in Mitigating Radiation- and Enzyme-Induced DNA Double-Strand Breaks by Homologous Recombination in Vertebrate Cells , 2003, Molecular and Cellular Biology.

[27]  K. Kamiya,et al.  Structure and Enzymatic Properties of a Stable Complex of the Human REV1 and REV7 Proteins* , 2003, The Journal of Biological Chemistry.

[28]  Magnar Bjørås,et al.  Human and bacterial oxidative demethylases repair alkylation damage in both RNA and DNA , 2003, Nature.

[29]  Samuel H. Wilson,et al.  Hypersensitivity of DNA polymerase beta null mouse fibroblasts reflects accumulation of cytotoxic repair intermediates from site-specific alkyl DNA lesions. , 2003, DNA repair.

[30]  P. Bates,et al.  Reversal of DNA alkylation damage by two human dioxygenases , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  G. Margison,et al.  Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. , 2002, Mutagenesis.

[32]  G. Margison,et al.  Heterogeneity of O6-Alkylguanine-DNA Alkyltransferase Activity in Colorectal Cancer: Implications for Treatment , 2002, Oncology.

[33]  Samuel H. Wilson,et al.  Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Santibanez-Koref,et al.  O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[35]  Junjie Chen,et al.  Histone H2AX Is Phosphorylated in an ATR-dependent Manner in Response to Replicational Stress* , 2001, The Journal of Biological Chemistry.

[36]  P. Karran.  Mechanisms of tolerance to DNA damaging therapeutic drugs. , 2001, Carcinogenesis.

[37]  T. Kunkel,et al.  Identification of an Intrinsic 5′-Deoxyribose-5-phosphate Lyase Activity in Human DNA Polymerase λ , 2001, The Journal of Biological Chemistry.

[38]  R. Kanaar,et al.  Repair of DNA interstrand cross-links. , 2001, Mutation research.

[39]  Samuel H. Wilson,et al.  5'-Deoxyribose Phosphate Lyase Activity of Human DNA Polymerase ɩ in Vitro , 2001, Science.

[40]  S C West,et al.  Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. , 2001, Molecular cell.

[41]  Thomas Ried,et al.  Response to RAG-mediated V(D)J cleavage by NBS1 and γ-H2AX , 2000 .

[42]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[43]  R. McLendon,et al.  Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Samuel H. Wilson,et al.  The lyase activity of the DNA repair protein β-polymerase protects from DNA-damage-induced cytotoxicity , 2000, Nature.

[45]  T. Lindahl,et al.  Quality control by DNA repair. , 1999, Science.

[46]  James Allan,et al.  3‐methyladenine DNA glycosylases: structure, function, and biological importance , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[47]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[48]  E. Rogakou,et al.  DNA Double-stranded Breaks Induce Histone H2AX Phosphorylation on Serine 139* , 1998, The Journal of Biological Chemistry.

[49]  H. Krokan,et al.  DNA glycosylases in the base excision repair of DNA. , 1997, The Biochemical journal.

[50]  S. Chaney,et al.  DNA repair: enzymatic mechanisms and relevance to drug response. , 1996, Journal of the National Cancer Institute.

[51]  Samuel H. Wilson,et al.  Requirement of mammalian DNA polymerase-β in base-excision repair , 1996, Nature.

[52]  Samuel H. Wilson,et al.  Requirement of mammalian DNA polymerase-β in base-excision repair , 1996, Nature.

[53]  A. Sancar.  Excision Repair in Mammalian Cells (*) , 1995, The Journal of Biological Chemistry.

[54]  S. Haas,et al.  O6‐methylguanine‐DNA methyltransferase activity in breast and brain tumors , 1995, International journal of cancer.

[55]  M. Shuford,et al.  p53 mutations, O6‐alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors , 1995, Cancer.

[56]  W. Thilly,et al.  An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[57]  G. Aquilina,et al.  Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage , 1993, Nature.

[58]  D. Beranek.  Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. , 1990, Mutation research.

[59]  B. Kaina,et al.  DNA repair and chromosomal stability in the alkylating agent-hypersensitive Chinese hamster cell line 27-1. , 1990, Mutation research.

[60]  H. Berg.  Cold Spring Harbor Symposia on Quantitative Biology.: Vol. LII. Evolution of Catalytic Functions. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1987, ISBN 0-87969-054-2, xix + 955 pp., US $150.00. , 1989 .

[61]  D. Scudiero,et al.  Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains , 1980, Nature.

[62]  R. Goth-Goldstein.  Inability of Chinese hamster ovary cells to excise O6-alkylguanine. , 1980, Cancer research.

[63]  M. Rajewsky,et al.  Persistence of O6-ethylguanine in rat-brain DNA: correlation with nervous system-specific carcinogenesis by ethylnitrosourea. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[64]  B. Kaina,et al.  Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. , 2009, DNA repair.

[65]  J. Cairncross,et al.  O 6-Methylguanine-DNA Methyltransferase Regulation by p 53 in Astrocytic Cells , 2007 .

[66]  G. Margison,et al.  Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. , 2003, The Lancet. Oncology.

[67]  Samuel H. Wilson,et al.  Mammalian DNA β-polymerase in base excision repair of alkylation damage , 2001 .

[68]  Samuel H. Wilson,et al.  DNA polymerase beta and mammalian base excision repair. , 2000, Cold Spring Harbor symposia on quantitative biology.

[69]  K. Kohn,et al.  Comparative pharmacokinetics of DNA lesion formation and removal following treatment of L1210 cells with nitrogen mustards. , 1990, Cancer communications.